Investment Analysts’ Updated EPS Estimates for March 25th (ABDP, AG, AKYA, ALIT, ANIX, ARTV, ASB, ATNM, AZEK, BAG)

Investment Analysts’ updated eps estimates for Tuesday, March 25th:

AB Dynamics (LON:ABDP) had its buy rating reaffirmed by analysts at Shore Capital.

AG.L (LON:AG) had its house stock rating reaffirmed by analysts at Shore Capital.

Akoya Biosciences (NASDAQ:AKYA) had its equal weight rating reiterated by analysts at Stephens. They currently have a $1.80 price target on the stock, down from their previous price target of $3.50.

Alight (NYSE:ALIT) had its outperform rating reaffirmed by analysts at Wedbush. They currently have a $11.00 price target on the stock.

Anixa Biosciences (NASDAQ:ANIX) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $7.00 price target on the stock.

Artiva Biotherapeutics (NASDAQ:ARTV) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $23.00 price target on the stock.

Artiva Biotherapeutics (NASDAQ:ARTV) had its outperform rating reiterated by analysts at Wedbush. They currently have a $18.00 target price on the stock.

Associated Banc (NYSE:ASB) had its equal weight rating reiterated by analysts at Stephens. Stephens currently has a $28.00 target price on the stock.

Actinium Pharmaceuticals (NYSE:ATNM) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $4.00 price target on the stock.

AZEK (NYSE:AZEK) had its neutral rating reaffirmed by analysts at Citigroup Inc.. They currently have a $51.50 target price on the stock, down from their previous target price of $61.00.

A.G. BARR (LON:BAG) had its house stock rating reissued by analysts at Shore Capital.

Brookfield Infrastructure Partners (NYSE:BIP) (TSE:BIP.UN) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $40.00 price target on the stock.

Bolt Biotherapeutics (NASDAQ:BOLT) had its neutral rating reiterated by analysts at HC Wainwright.

Brown & Brown (NYSE:BRO) had its equal weight rating reissued by analysts at Morgan Stanley. They currently have a $128.00 price target on the stock.

CG Oncology (NASDAQ:CGON) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $75.00 target price on the stock.

CorMedix (NASDAQ:CRMD) had its buy rating reiterated by analysts at D. Boral Capital. The firm currently has a $15.00 target price on the stock.

Dun & Bradstreet (NYSE:DNB) had its hold rating reiterated by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a $9.15 target price on the stock, down from their previous target price of $11.00.

EOG Resources (NYSE:EOG) had its neutral rating reaffirmed by analysts at Mizuho. Mizuho currently has a $140.00 target price on the stock, down from their previous target price of $148.00.

Energy Transfer (NYSE:ET) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $23.00 target price on the stock.

FD Technologies (LON:FDP) had its buy rating reaffirmed by analysts at Shore Capital.

FOX (NASDAQ:FOXA) had its buy rating reaffirmed by analysts at Guggenheim. Guggenheim currently has a $60.00 price target on the stock.

Gamma Communications (LON:GAMA) had its buy rating reissued by analysts at Shore Capital.

Genelux (NASDAQ:GNLX) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $30.00 price target on the stock.

HEICO (NYSE:HEI) had its outperform rating reiterated by analysts at William Blair.

HSBC (LON:HSBA) had its buy rating reaffirmed by analysts at Bank of America Co.. They currently have a GBX 1,035 ($13.37) target price on the stock.

Inter Parfums (NASDAQ:IPAR) had its buy rating reissued by analysts at DA Davidson. DA Davidson currently has a $170.00 target price on the stock.

KB Home (NYSE:KBH) had its neutral rating reaffirmed by analysts at Wedbush. Wedbush currently has a $75.00 target price on the stock.

Lovesac (NASDAQ:LOVE) had its buy rating reaffirmed by analysts at DA Davidson. They currently have a $35.00 target price on the stock.

Larimar Therapeutics (NASDAQ:LRMR) had its buy rating reaffirmed by analysts at Guggenheim. They currently have a $26.00 price target on the stock.

Intuitive Machines (NASDAQ:LUNR) had its buy rating reissued by analysts at Benchmark Co.. They currently have a $16.00 price target on the stock.

Lexeo Therapeutics (NASDAQ:LXEO) had its buy rating reiterated by analysts at Chardan Capital. They currently have a $25.00 target price on the stock.

MasTec (NYSE:MTZ) had its buy rating reaffirmed by analysts at Guggenheim. The firm currently has a $195.00 price target on the stock.

Mural Oncology (NASDAQ:MURA) had its hold rating reaffirmed by analysts at Jones Trading.

MicroVision (NASDAQ:MVIS) had its buy rating reiterated by analysts at Westpark Capital. The firm currently has a $2.00 target price on the stock.

MicroVision (NASDAQ:MVIS) had its buy rating reaffirmed by analysts at D. Boral Capital. D. Boral Capital currently has a $3.00 price target on the stock.

Neurogene (NASDAQ:NGNE) had its outperform rating reissued by analysts at William Blair.

OncoCyte (NASDAQ:OCX) had its equal weight rating reissued by analysts at Stephens. Stephens currently has a $4.00 price target on the stock.

OncoCyte (NASDAQ:OCX) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $4.25 target price on the stock.

Oklo (NYSE:OKLO) had its outperform rating reiterated by analysts at Wedbush. The firm currently has a $45.00 price target on the stock.

Opthea (NASDAQ:OPT) had its underperform rating reiterated by analysts at Jefferies Financial Group Inc.. They currently have a $1.00 target price on the stock, down from their previous target price of $8.00.

Regional REIT (LON:RGL) had its house stock rating reaffirmed by analysts at Shore Capital.

Cassava Sciences (NASDAQ:SAVA) had its neutral rating reiterated by analysts at HC Wainwright. They currently have a $2.00 target price on the stock.

Sprouts Farmers Market (NASDAQ:SFM) had its sector perform rating reiterated by analysts at Royal Bank of Canada. They currently have a $160.00 price target on the stock.

Surgery Partners (NASDAQ:SGRY) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. The firm currently has a $35.00 target price on the stock.

Solaris Resources (NYSEAMERICAN:SLSR) had its hold rating reaffirmed by analysts at Maxim Group.

Titon (LON:TON) had its house stock rating reaffirmed by analysts at Shore Capital.

Ultimate Products (LON:ULTP) had its buy rating reiterated by analysts at Canaccord Genuity Group Inc.. They currently have a GBX 130 ($1.68) price target on the stock.

Ultimate Products (LON:ULTP) had its house stock rating reaffirmed by analysts at Shore Capital.

Verve Therapeutics (NASDAQ:VERV) had its buy rating reiterated by analysts at Guggenheim.

Verve Therapeutics (NASDAQ:VERV) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $15.00 target price on the stock.

Corporación Inmobiliaria Vesta (NYSE:VTMX) had its sell rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They currently have a $21.00 target price on the stock, down from their previous target price of $31.00.

NCR Voyix (NYSE:VYX) had its outperform rating reiterated by analysts at Royal Bank of Canada. The firm currently has a $17.00 target price on the stock.

Verizon Communications (NYSE:VZ) had its sector perform rating reissued by analysts at Royal Bank of Canada. They currently have a $45.00 price target on the stock, up from their previous price target of $42.00.

Wynnstay Group (LON:WYN) had its house stock rating reiterated by analysts at Shore Capital.